Inclusion Criteria:

- Biopsy proven nasopharyngeal carcinoma – WHO type 3 (recurrence or metastases)

- metastatic disease or locally recurrent disease not amendable curative therapy

- Patients must have measurable disease

- least one (not more than a total of three prior lines of chemotherapy for metastatic
or recurrent disease). This must include at least 1 prior line of platinum-containing
chemotherapy.

- An ECOG performance status of 0–2

- Absolute neutrophil count (ANC) ≥1500/mm3

- Hemoglobin  8g/dl (blood transfusion is allowed to correct hemoglobin level).

- PLT ≥ 75,000/mm 3

- Total bilirubin ≤ 2 x upper normal limit (UNL)

- Serum ALT ≤ 5 x UNL

- Serum creatinine ≤ 2 mg/dL

- Serum albumin ≥ 2.5 g/dL

- No known history of brain or leptomeningeal metastasis.

- ≥ 18 years of age.

- Estimated life expectancy ≥ 24 weeks.

- For sexually active women of childbearing potential, negative pregnancy test within
21 days of enrolling on trial.

- must be able to give informed written consent

Exclusion Criteria:

- Patients who have not had at least 1 or more than 3 previous lines of treatment for
metastatic or recurrent NPC

- Prior BORTEZOMIB therapy

- Immunotherapy ≤ 4 weeks have elapsed prior to study entry

- Biologic therapy ≤ 4 weeks have elapsed prior to study entry

- Radiation therapy ≤ 4 weeks have elapsed prior to study entry

- Major surgery, or significant traumatic injury ≤3 weeks prior to study entry

- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or
supportive care considered investigational

- Evidence of CNS involvement

- Presence of > grade 1 sensory peripheral neuropathy of any etiology OR grade 1 with
neuropathic pain of any etiology.

- Patients with significant local symptoms from metastases which is amenable to
radiotherapy

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to BORTEZOMIB.

- History of other malignancy ≤ 3 years prior to study entry, except for adequately
treated basal cell, squamous cell skin cancer or cervical intraepithelial neoplasia.

- Uncontrolled intercurrent illness

- Patients who are pregnant or breast feeding (Sexually active men and women of
childbearing potential must use contraception during course of therapy and within 3
months of completion of trial) Participation in another clinical trial involving
therapeutic intervention within 4 weeks of enrollment.

- Known history of HIV